Available online at www.sciencedirect.com

SCIENCE DIRECT®

Contraception

Contraception 70 (2004) 507–509

Author Index
Volume 70
July–December, 2004

Abercrombie, T., 241
Abuabara, K., 127
Acar, M., 467
Affandi, B., 433
Aissa, R.B., 451
Akin, A., 401
Aldrighi, J.M., 65
Alvarez, F., 442
Amaral, E., 492
Anderson, R.A., 415
Andrade, A.T.L., 173
Andrade, G.N., 173
Andrist, L.C., 359
Archer, D.F., 77, 227, 241, 327
Arias, R.D., 359
Arons, A., 31

Bachmann, G., 191
Baerwald, A.R., 371
Bahi, N., 437
Bajpai, M., 429
Ballagh, S.A., 77, 227, 241
Barnhart, K.T., 227, 233, 498
Baumrind, N., 31
Bax, R., 221, 227, 233
Benda, N., 191
Bernstein, L., 407
Bilgili, N., 401
Biswas, A., 379
Biswas, S., 379
Blanchard, K., 307
Bley, J., 31
Blum, J., 401, 487
Bode, F.R., 11, 269
Borgatta, L., 121
Boulanger, J., 359, 442, 451
Brothers, L.P, 183

Cai, S.Z., 153
Callahan, M.M., 77, 221, 227, 233, 241
Carbonell, J.L.L., 55
Carl, J., 281
Carreras, R., 199
Castro, L.J., 423
Cevrioglu, A.S., 467
Chany II, C., 415
Checa, M.A., 199
Chélli, H., 487
Chen, A., 121
Cheung, K.-B., 474
Chu, C.C., 213
Chung, T.K.H., 474
Clark, V.A., 407
Cochon, L., 442
Coffee, A., 281
Coksuer, H., 467
Conard, J., 437
Creinin, M.D., 77, 227, 233, 289, 313
Cremer, M., 506
Croxatto, H.B., 47, 442
Cruz, A.M., 365
Cui, G.-H., 203, 335
Cundiff, D.L., 3
Cwiak, C., 383

d'Arcangues, C., 47, 451
da Cunha Bastos, Á., 365
Dabash, R., 487
Dadhwal, V., 117
Darney, P.D., 31
de Melo, N.R., 65
Degirmenci, B., 467
Delgado, E., 55
Demirel, R., 467
Dévényi, L., 149
Di Capua, E., 352
Diao, X.-H., 415
Diez, M.J., 423
Djanhan, Y., 319
Dominguez, L., 359
Dutton, C., 11

Ellertson, C., 127
Elsen, R., 107
Emmert, S., 359
Erol, D., 467
Espinoza, H., 127
Etzi, R., 293

Fabrini, P., 365
Faggion, Jr., D., 65
Fairhurst, K., 25
Faulder, G.S., 135
Faundes, A., 442
Faúndes, A., 492
Feathergill, K., 415
Fernandes, C.E., 65
Fernández, N., 423
Fiala, C., 387
Fielding, S.L., 41
Floris, S., 293
Forcelledo, M.L., 442
Foster, D.G., 31
Fratta, S., 293
Frederiksen, M.C., 61
Frezieres, R.G., 221, 407
Fuentealba, B., 47
Fulcheri, E., 352

Gabelnick, H.L., 241
García, J.J., 423
Gellasch, T., 383
Gemzell-Danielsson, K., 387
Gilliam, M.L., 299
Girling, J.E., 343
Gittinger, E., 121
Glantz, R., 73
Glasier, A., 25, 135
Godfrey, E.M., 41
Goldstein, C., 299
González, A., 423
Gopalakrishnan, I., 281
Gospin, R.M., 213
Goyaux, N., 319
Grams, M., 19
Grimes, D. A., 357
Gueddana, N., 487
Guerriero, S., 293
Guichard, L., 107
Guo, Y., 203
Gupta, G., 429

Hajri, S., 487
Hall, C.E., 73

0010-7824/$ – see front matter © 2004 Elsevier Inc. All rights reserved.

Hazelden, C., 451
Hellborg, M., 387
Helström, L., 387
Henry, D., 241
Heryanto, B., 343
Ho, P.C., 159
Horellou, M.-H., 437
Hwang, A.C., 1, 87, 179, 265, 357, 435

Induni, M., 31
Ingram, M.J., 73
Iweala, O.I., 141

Jain, J., 11, 269
Jakimiuk, A.J., 269
Jensen, J.T., 111

Kahraman, A., 467
Kan, A.S.Y., 159
Kaunitz, A.M., 269, 359, 506
Keshri, G., 429
Keverline, S., 289
Khader, Y., 85
Kirca, Ü., 401
Koçoğlu, G., 401
Kriengsinyot, R., 307
Kuehl, T.J., 281
Kuhl, H., 97
Kumar, S., 117
Kutschera, E., 97

Lai, J.-J., 77
Lakshmi, V., 429
Larson, E., 65
Ledger, W.J., 213
Lee, J.H., 97
Lei, H., 153
Lello, S., 293
Li, R.H.W., 474
Lichtenberg, E.S., 61
Liechtenstein-Zábrák, J., 111
Llorente, M., 55
Lo, S.S.T., 474

Maazoun, L., 487
Machado, R.B., 365
Maguire, R.A., 107
Maia, E., 365
Malamud, D., 498
Mallarini, G., 293
Marí, J., 55
Marr, J., 191
Massai, M.R., 47
Massai, R., 442, 451
Matsuda, T., 319
Mauck, C.K., 77, 221, 227, 233, 241, 492
Mawson, J.T., 41
McCarthy, T., 351
Melis, G.B., 293
Meyn, L.A., 289, 313
Mikanda, J., 31
Mirkin, S., 327
Mishell, Jr., D.R., 11
Mitchel, M.J., 483
Mittal, S., 117
Morroni, C., 19
Mullally, B., 121
Musselman, B.L., 359

Nelson, A.L., 407
Ng, E.H.Y., 159
Nicosia, A., 11
Nilas, L., 393
Nørgaard, M., 393
Nucatola, D., 359

Olatunbosun, O.A., 371
Önderoğlu, L., 401
Orrù, M., 293
Özalp, S., 401

Paoletti, A.M., 293
Pascual, J., 199
Patai, K., 149
Patel, N., 343
Pavez, M., 47, 442
Peacock, K., 407
Pelissier, C., 437
Perdigão, A., 492
Petitti, D.B., 3
Philip, N., 183, 401
Phillips, D.M., 107
Phupong, V., 307
Piaggio, G., 451
Pierson, R.A., 371
Pinol, A., 451
Plu-Bureau, G., 437
Pretorius, E.S., 498
Pymar, H.C., 77

Quesenberry, Jr., C.P., 3

Ranuzzi, F., 293
Reiter, S., 359
Rekers, H., 433
Rencher, W.F., 77, 415
Reyes, V.R.O.Y., 65
Riley, S.C., 135
Robles, A., 199
Rodríguez, J., 55
Rodriguez, M.I., 111
Rogers, P.A.W., 343
Rørbye, C., 393
Rosendaal, F.R., 85
Ross, D., 269
Rossi, B., 313
Rowe, P.J., 165, 169, 173

Sánchez, C., 55
Saadi, H., 487
Sahagún, A., 423
Salvador, I., 55
Salvatierra, A.M., 442
Sampson-Landers, C., 191
Saxena, B.B., 213
Schaff, E.A., 41
Schmitz, S.W., 221, 227
Schwartz, J.L., 77
Seaman, P., 25
Setty, B.S., 429
Shabbout, M., 498
Shannon, C., 183
Sharma, Y., 117
Shera, D., 498
Shields, W.C., 1, 87, 179, 265, 357, 435
Sidney, S., 3
Sierra, M., 423
Singh, M., 213
Sivin, I., 353
Soff, G.A., 3
Sorge, R., 293
Souza, J.B., 65
Souza, J.P., 173
Souza, M.H., 492
Sriyirojana, N., 307
Stanwood, N.L., 41
Stewart, F., 1, 31, 87, 179, 265, 435
Stone, N., 135
Subakir, S.B., 451
Sudol, K.M., 107
Su-juan, G., 451
Sulak, P.J., 191, 281

Taneepanichskul, S., 277, 307
Tantiwattanakul, P., 277
Tapia, B., 299
Taylor, C.L., 107
Teh, D.K.G., 474
Thalabard, J.-C., 437
Thistle, P., 483
Thonneau, P., 319
Tiezzi, L., 19

Timbers, K., 498
Tolan, K.K., 3
Tong, N.-C., 474
Trouton, K., 463
Trussell, J., 89
Tsui, M.H.Y., 474

Valera, L., 55
Valero, F., 55
Vargas, F., 55
Viegas, O.A.C., 379
Vimala, N., 117
Vragovic, O., 121

Wajszczuk, C., 11
Waller, D., 415, 492
Walsh, T.L., 221, 407
Warden, M., 299
Weiner, D.H., 77, 233
Welffens, C., 319
Westhoff, C., 19
Wiebe, E.R., 463
Wiegratz, I., 97
Wildemeersch, D., 165, 169, 173, 354
Winikoff, B., 183, 307, 387, 401, 487
Winkler, U.H., 97
Wraxall, B.G.D., 407
Wyke, S., 25

Xia, X.P., 153
Xie, C.S., 153
Xu, T., 153
Xu, Y.-Y., 335
Xu, Z.-L., 335
Xue, S.-P., 203, 335

Yace-Soumah, F., 319
Yang, Z.-J., 203, 335
Ye, W.-S., 203
Yilmazer, M., 467

Zalanyi, S., 111
Zaneveld, L., 415, 492
Zedda, P., 293
Zelkó, R., 149
Ziebland, S., 25
Zieman, M., 383

Available online at www.sciencedirect.com

SCIENCE DIRECT®

Contraception

ELSEVIER

Contraception 70 (2004) 510–513

Subject Index
Volume 70
July–December, 2004

Abstracts, ARHP 2004 conference, Advances in Reproductive Health session, 251
Acceptability, Norplant vs tubal ligation, 483
AcidForm,
  bioadhesive gel, 492
  spermicial effect, 492
Advance provision, EC, 25
Aspirin and/or vitamin E, effect on Norplant-induced bleeding, 451
Assessment techniques, cervicovaginal epithelium, 241
Association of Reproductive Health Professions (ARHP) editorial,
  2005 United States budget, 87
  goals for reproductive health, 1
  new beginning to end HIV/AIDS in the new year, 435
  prescription for real security, 179
  ten priorities for women's health, 265
  universal insurance coverage for contraception, 357
Attitudes,
  extended use OCs, 359
  menstrual suppression, 359
Attitudes and practices, peripartum contraception, 383

Bioavailability of ethinylestradiol, effect of glucomannan (rabbit), 423
Bleeding pattern, effect of mifepristone in Norplant users, 47
Body fat, effect of ethinylestradiol + gestodene, 65
Bone metabolism, effect of ethinylestradiol + drospirenone, 293
Breakthrough bleeding management, extended OC with short hormone-free interval, 281
Bridge method, alternative to standard DMPA initiation protocol, 19
Buccal vs vaginal administration, misoprostol, 463

C31G,
  male tolerance study, 221
  mixture of cetyl betaine + myristamine oxide, 221
  postcoital testing study, 227
  vaginal contraceptive and microbicide, 221
  vaginal safety study, 233
Cervical epithelium, assessment techniques, 241
Cesarean scar dehiscence, cause of hemorrhage after second-trimester abortion, 61
Chloramidinone acetate, use in women at high risk of venous thromboembolism, 437
Clinical effects, ethinylestradiol + gestodene, 365
Complaints with use of IUDs, relation to surface morphology and composition, 149
Complication of induced abortion, determinants of maternal deaths, 319
Contraceptive effect, formulated Ushercell (rabbit), 415
Contraceptive efficacy,
  mifepristone weekly vs postcoital regimen, 41
  subcutaneous DMPA, 269
Contraceptive failure in US, review, 89
Contraceptive methods, impact on quality of life and sexual function, 474
Contraceptive side effects, perceptions and attitudes, 299
Contraceptive use and risk of unintended pregnancy, 31
Copper-levonorgestrel-releasing IUS, effect on menstrual blood loss, 169

Depot-medroxyprogesterone acetate (DMPA),
  low-dose subcutaneous formulation, 11, 269
  pharmacokinetics/pharmacodynamic study, 11
Diagnostic tests for HIV, overview, 141
DMPA (depot-medroxyprogesterone acetate)
DMPA initiation, alternative to standard protocol, 19
DMPA users, effect of mefenamic acid on bleeding control, 277

EC (emergency contraception)
Effectiveness, male latex condoms, 407
Efficacy,
  ethinylestradiol + drospirenone, 191
  nonhormonal vaginal contraceptives from hydrogel delivery system (rabbit), 213
Emergency contraception (EC),
  advance provision, 25
  levonorgestrel, 442
  trends in use, 199
Endometrial effects, mifepristone, 327
Endometrial vasculature, effect of progestin treatment (mouse), 343
Estrogen-progestin OC use, risk of venous thromboembolic disease, 3
Ethinylestradiol + dienogest, effect on hemostatic parameters, 97

0010-7824/$ – see front matter © 2004 Elsevier Inc. All rights reserved.

Ethinylestradiol + drospirenone,
effect on bone metabolism, 293
efficacy and safety, 191
Ethinylestradiol + estradiol valerate + dienogest, effect on hemostatic parameters, 97
Ethinylestradiol + gestodene,
clinical and metabolic effects, 365
effect on body fat, 65
Ethinylestradiol + levonorgestrel, effect on hemostatic parameters, 97
Etonogestrel, effect on liver function, 379
Extended OC with short hormone-free interval,
ethinylestradiol + drospirenone, 191
management of breakthrough bleeding, 281
Extended use OCs, attitudes, 359
Extra Strength Gynol II, vaginal safety study, 233

Failure of contraception in US, review, 89
Female sterilization, effect of transcervical polidocanol (rat, monkey), 111
Filshie clip vs Pomeroy technique, sterilization, 506
Frameless copper-releasing IUD, effect on menstrual blood loss, 169, 173

Glucomannan, effect on oral bioavailability of ethinylestradiol (rabbit), 423
Gossypol + methyltestosterone/ethinylestradiol, male OC (rat), 333
Gossypol acetic acid with desogestrel/ethinylestradiol/testosterone undercanoate, male OC (rat), 203
GyneFix® 200 IUS, efficacy and acceptability, 353
Gynol II vaginal gel distribution, MRI evaluation, 498

Hemostatic parameters, effect of OCs, 97
HIV (human immunodeficiency virus)
HIV diagnostic tests, overview, 141
Home-use of misoprostol, acceptability, 387
Hormone-free interval of OC use, ovarian folilicular development, 371
Hydrogel delivery system, nonhormonal vaginal contraceptives, 213

Implanon studies conducted in Indonesia, retraction of results, 433
Implant contraceptive,
etonogestrel, 379
levonorgestrel, 47, 379, 483
Incomplete abortion, treatment with misoprostol, 307
Ideopathic menorrhagia, effect of levonorgestrel-releasing IUS, 165
Induced abortion complications, determinants of maternal deaths, 319
Infection after medical abortion, review, 183
Initiation of DMPA, alternative to standard protocol, 19
Injectable contraceptive, depot-medroxyprogesterone acetate, 11, 269
Intrauterine device (IUD),
frameless copper-releasing, 169, 173
surface morphology and composition in relation to complaints, 149
Intrauterine system (IUS),
copper-levonorgestrel-releasing, 169
levonorgestrel-releasing, 165, 173
Introductory clinical study, mifepristone + misoprostol, 401
IUD (intrauterine device)
IUD development, nano-Cu/low-density polyethylene composite, 183
IUS (Intrauterine system)

Knowledge and attitudes of physicians, medication abortion, 127

Levonorgestrel,
effect on endometrial vasculature (mouse), 343
effect on liver function, 379
Levonorgestrel EC, effect on pituitary-ovarian function, 442
Levonorgestrel-releasing IUS, effect on menstrual blood loss, 169, 173
Liver function,
effect of etonogestrel, 379
effect of levonorgestrel, 379
Low-estrogen dose OCs, risk of venous thromboembolic disease, 3

Male latex condoms, effectiveness, 407
Male OC,
gossypol + methyltestosterone/ethinylestradiol (rat), 335
gossypol acetate acid + desogestrel/ethinylestradiol/testosterone undecanoate (rat), 203
Male tolerance study, C31G, 221
Maternal deaths determinante, induced abortion complications, 319
Medical abortion,
experience in developing country, 487
infection, review, 183
introductory clinical study, 401
methotrexate + misoprostol, 463
mifepristone + misoprostol, 313, 487
misoprostol as primary agent, 121
Medical students, effect of sex education on dealing with sexual health issues, 135
Medical vs surgical abortion, comparison of outcome measures, 393
Medication abortion, physicians' knowledge and attitudes, 127
Medroxyprogesterone acetate, effect on endometrial vasculature (mouse), 343
Mefenamic acid, effect on bleeding control in DMPA users, 277

Menstrual blood loss,
effect of copper-levonorgestrel-releasing IUS, 169
effect of frameless copper-releasing IUD, 169, 173
effect of levonorgestrel-releasing IUS, 165, 173
Menstrual cycle regularity, analysis, 289
Menstrual suppression, attitudes, 359
Metabolic effects, ethinylestradiol + gestodene, 365
Methods of contraception, probabilities of failure, 89
Methotrexate + misoprostol, medical abortion, 463
Mifepristone,
contraceptive efficacy of weekly vs postcoital regimen, 41
effect on bleeding pattern in Norplant users, 47
endometrial affects, 327
Mifepristone + misoprostol,
ability to predict outcome of medical abortion, 313
experience in developing country, 487
introductory clinical study, 401
Misoprostol,
acceptability of home-use, 387
buccal vs vaginal administration, 463
primary agent for medical abortion, 121
second-trimester abortion, 55
sublingual vs vaginal administration for cervical priming, 117
treatment of incomplete abortion, 307
MRI evaluation, vaginal gel distribution, 498
Myocardial infarction risk, effect of OC use, 85

Nano-Cu/low-density polyethylene composite, IUD development, 153
New beginning to end HIV/AIDS in the new year, ARHP editorial, 435
Nitric oxide-releasing derivative of nonoxynol-9,
spermicidal activity, 73
synthesis, 73
Nonhormonal vaginal contraceptives, hydrogel delivery system, 213
Nonoxynol-9, spermicidal effect, 492
Nonoxynol-9 lubricants, effect on transmission of HIV and other STIs, 107
Norplant, acceptability, 483
Norplant implant users, effect of mifepristone on bleeding pattern, 47
Norplant-induced bleeding, effect of vitamin E and/or aspirin, 451

OC (oral contraceptive)
OC extended regimen with short hormone-free interval, breakthrough bleeding management, 281
ethinylestradiol + drospirenone, 191
OC use, risk of venous thromboembolic disease, 3
OC use and risk of myocardial infarction, 85
Oral contraceptive (OC),
chlormadinone acetate, 437
ethinylestradiol + dienogest, 97
ethinylestradiol + drospirenone, 191, 293
ethinylestradiol + estradiol valerate + dienogest, 97
ethinylestradiol + gestodene, 65, 365
ethinylestradiol + levonorgestrel, 97
ovarian follicular development during use, 371
Outcome measures comparison, medical vs surgical abortion, 393
Outcome of mifepristone + misoprostol medical abortion, ability to predict, 313
Ovarian follicular development, during OC use, 371
Ovarian function, effect of levonorgestrel EC, 442
Ovarian hormone secretion, effect of tubal sterilization, 467
Ovulation, effect of DMPA, 11

Paracervical block techniques, effect on pain relief during suction evacuation, 159
Perceptions and attitudes, contraceptive side effects, 299
Peripartum contraception, attitudes and practices, 383
Pharmacokinetics, DMPA, 11
Pituitary-ovarian function, effect of levonorgestrel EC, 442
Plant extracts, pregnancy interceptive action (rat), 429
Polidocanol, nonsurgical female sterilization method (rat, monkey), 111
Polystyrene sulfonate gel,
development as vaginal contraceptives and microbicide, 77
safety profile and acceptability, 77
Postcoital testing study, C31G, 227
Pregnancy despite IUD, 351
Pregnancy interceptive action, plant extracts (rat), 429
Prescription for real security, ARHP editorial, 179

Regularity of menstrual cycles, analysis, 289
Reproductive health goals, ARHP editorial, 1
Retraction of results, Implanon studies conducted in Indonesia, 433

Quality of life, impact of contraceptive measures, 474

Safety,
ethinylestradiol + drospirenone, 191
subcutaneous DMPA, 269
Second-trimester abortion,
cesarean scar dehiscence as cause of hemorrhage, 61
use of misoprostol, 55
Sex education for medical students, effect on dealing with sexual health issues, 135
Sexual function, impact of contraceptive methods, 474
Spermicidal activity, nitric oxide-releasing derivative of nonoxynol-9, 73
Spermicidal effects,
AcidForm, gel, 492
nonoxynol-9, 492
STIs (sexually transmitted infections)
Sublingual vs vaginal misoprostol, effect on cervical priming, 117

Suction evacuation, effect of paracervical block techniques on pain relief, 159

Techniques to assess cervicovaginal irritation, 241
Ten priorities for women's health, ARHP editorial, 205
Transmission of HIV and other STIs, effect of lubricants containing nonoxynol-9, 107
Trends in use of EC, 199
Tubal ligation, acceptability, 483
Tubal sterilization, effect on utero-ovarian circulation, 467

Unintended pregnancy risk and contraceptive use, 31
United States budget 2005, ARHP editorial, 87
Universal insurance coverage for contraceptives, ARHP editorial, 357
Ushercell™ formulation,
cellulose sulfate, 415
contraceptivevs effect (rabbit), 415
Utero-ovarian circulation, effect of tubal sterilization, 467

Vaginal gel distribution, MRI evaluation, 498
Vaginal safety study,
C31G, 233
Extra Strength Gynol II, 233
Vaginal vs buccal administration, misoprostol, 463
Venous thromboembolic disease, use of estrogen-progestin OC, 3
Venous thromboembolism, use of chlormadinone acetate in women at high risk, 437
Vitamin E and/or aspirin, effect on Norplant-induced bleeding, 451